Dirk Zboralski

1.6k total citations · 1 hit paper
22 papers, 937 citations indexed

About

Dirk Zboralski is a scholar working on Oncology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Dirk Zboralski has authored 22 papers receiving a total of 937 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Oncology, 11 papers in Molecular Biology and 7 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Dirk Zboralski's work include Peptidase Inhibition and Analysis (6 papers), Radiopharmaceutical Chemistry and Applications (5 papers) and Chemokine receptors and signaling (5 papers). Dirk Zboralski is often cited by papers focused on Peptidase Inhibition and Analysis (6 papers), Radiopharmaceutical Chemistry and Applications (5 papers) and Chemokine receptors and signaling (5 papers). Dirk Zboralski collaborates with scholars based in United States, Germany and France. Dirk Zboralski's co-authors include Dirk Eulberg, Anna Kruschinski, Christian Maasch, Axel Vater, Kai Hoehlig, William G. Wierda, Michael J. Keating, Jan A. Burger, Julia Hoellenriegel and Nathalie Y. Rosin and has published in prestigious journals such as Blood, Cancer Research and Oncogene.

In The Last Decade

Dirk Zboralski

22 papers receiving 915 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using ¹⁷⁷Lu-FAP-2286: First-in-Humans Results

2021 210 citations Richard P. Baum, Christiane Schuchardt et al. Journal of Nuclear Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Dirk Zboralski United States	13	503	332	218	149	135	22	937
Silke Aigner Germany	10	429 0.9×	469 1.4×	286 1.3×	78 0.5×	87 0.6×	18	1.1k
Tad Kornaga United States	8	250 0.5×	400 1.2×	359 1.6×	53 0.4×	119 0.9×	12	870
Gabriel J. Villares United States	18	330 0.7×	666 2.0×	241 1.1×	39 0.3×	126 0.9×	19	1.2k
Maya Zigler United States	17	300 0.6×	565 1.7×	273 1.3×	61 0.4×	122 0.9×	23	961
Diane Tseng United States	11	701 1.4×	417 1.3×	803 3.7×	91 0.6×	147 1.1×	21	1.5k
George S. Laszlo United States	15	401 0.8×	435 1.3×	208 1.0×	93 0.6×	224 1.7×	35	814
Philippe Pujuguet Belgium	16	446 0.9×	542 1.6×	112 0.5×	63 0.4×	34 0.3×	22	1.1k
Cécile Rouleau United States	16	241 0.5×	444 1.3×	93 0.4×	64 0.4×	53 0.4×	26	732
Clotilde Billottet France	14	268 0.5×	408 1.2×	193 0.9×	29 0.2×	88 0.7×	21	823
Jenny Paupert Belgium	15	313 0.6×	311 0.9×	81 0.4×	85 0.6×	36 0.3×	23	683

Countries citing papers authored by Dirk Zboralski

Since Specialization

Citations

This map shows the geographic impact of Dirk Zboralski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dirk Zboralski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dirk Zboralski more than expected).

Fields of papers citing papers by Dirk Zboralski

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dirk Zboralski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dirk Zboralski. The network helps show where Dirk Zboralski may publish in the future.

Co-authorship network of co-authors of Dirk Zboralski

This figure shows the co-authorship network connecting the top 25 collaborators of Dirk Zboralski. A scholar is included among the top collaborators of Dirk Zboralski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dirk Zboralski. Dirk Zboralski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Wiedemann, Norbert, Aileen Hoehne, Frank Osterkamp, et al.. (2024). Preclinical Characterization of DPI-4452: A⁶⁸Ga/¹⁷⁷Lu Theranostic Ligand for Carbonic Anhydrase IX. Journal of Nuclear Medicine. 65(5). 761–767. 16 indexed citations

Zboralski, Dirk, Frank Osterkamp, Aileen Hoehne, et al.. (2023). Fibroblast activation protein targeted radiotherapy induces an immunogenic tumor microenvironment and enhances the efficacy of PD-1 immune checkpoint inhibition. European Journal of Nuclear Medicine and Molecular Imaging. 50(9). 2621–2635. 27 indexed citations

Zboralski, Dirk, Aileen Hoehne, Matthias Paschke, et al.. (2022). Abstract 3317: Comparative biodistribution and radiotherapeutic efficacy of the fibroblast activation protein (FAP)-targeting agents FAP-2286 and FAPI-46. Cancer Research. 82(12_Supplement). 3317–3317. 4 indexed citations

Baum, Richard P., Christiane Schuchardt, Aviral Singh, et al.. (2021). Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using ¹⁷⁷Lu-FAP-2286: First-in-Humans Results. Journal of Nuclear Medicine. 63(3). 415–423. 210 indexed citations breakdown →

Kwan, Tanya T., Minh Nguyen, Dirk Zboralski, et al.. (2021). Abstract LBA032: Pan-cancer analysis of fibroblast activation protein alpha (FAP) expression to guide tumor selection for the peptide-targeted radionuclide therapy FAP-2286. Molecular Cancer Therapeutics. 20(12_Supplement). LBA032–LBA032. 4 indexed citations

Zboralski, Dirk, Frank Osterkamp, Andrew D. Simmons, et al.. (2020). 571P Preclinical evaluation of FAP-2286, a peptide-targeted radionuclide therapy (PTRT) to fibroblast activation protein alpha (FAP). Annals of Oncology. 31. S488–S488. 14 indexed citations

Baum, Richard P., Maythinee Chantadisai, Christiane Smerling, et al.. (2020). Peptide-Targeted Radionuclide Therapy (PTRT) using Lu-177 FAP-2286 in Diverse Adenocarcinomas: Feasibility, Biodistribution and Preliminary Dosimetry in a First-in-human study. 61. 633–633. 4 indexed citations

Zboralski, Dirk, et al.. (2018). Generation and Harnessing of Heterotypic Tumor-Stroma Spheroids to Study Cancer Immunosurveillance. Methods in molecular biology. 1884. 269–281. 3 indexed citations

Ludwig, Heinz, Katja Weisel, Maria Teresa Petrucci, et al.. (2017). Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib–dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study. Leukemia. 31(4). 997–1000. 60 indexed citations

10.

Zboralski, Dirk, et al.. (2017). Increasing Tumor-Infiltrating T Cells through Inhibition of CXCL12 with NOX-A12 Synergizes with PD-1 Blockade. Cancer Immunology Research. 5(11). 950–956. 135 indexed citations

11.

Zboralski, Dirk, Anna Kruschinski, Dirk Eulberg, & Axel Vater. (2016). CXCL12 inhibition with NOX-A12 (olaptesed pegol) increases T and NK cell infiltration and synergizes with immune checkpoint blockade in tumour-stroma spheroids. Annals of Oncology. 27. vi371–vi371. 1 indexed citations

12.

Zboralski, Dirk, Anna Kruschinski, & Axel Vater. (2016). CXCL12 Inhibition By Nox-A12 (Olaptesed Pegol) Synergizes with the ADCC Activity of CD20 Antibodies By Increasing NK Cell Infiltration in a 3D Lymphoma Model. Blood. 128(22). 3021–3021. 2 indexed citations

13.

Chernikova, Sophia B., Jason H. Stafford, Taichang Jang, et al.. (2013). Blockade of SDF-1 after irradiation inhibits tumor recurrences of autochthonous brain tumors in rats. Neuro-Oncology. 16(1). 21–28. 73 indexed citations

14.

Hoellenriegel, Julia, Dirk Zboralski, Christian Maasch, et al.. (2013). The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization. Blood. 123(7). 1032–1039. 179 indexed citations

15.

Schwoebel, Frank, Lucas T. van Eijk, Dirk Zboralski, et al.. (2013). The effects of the anti-hepcidin Spiegelmer NOX-H94 on inflammation-induced anemia in cynomolgus monkeys. Blood. 121(12). 2311–2315. 120 indexed citations

16.

Roccaro, Aldo M., Antonio Sacco, Marco Ungari, et al.. (2012). In Vivo Targeting of Stromal-Derived Factor-1 As a Strategy to Prevent Myeloma Cell Dissemination to Distant Bone Marrow Niches. Blood. 120(21). 440–440. 3 indexed citations

17.

Hoellenriegel, Julia, Dirk Zboralski, Zeev Estrov, et al.. (2011). The Spiegelmer Nox-A12, a Novel SDF-1 (CXCL12) Inhibitor, and Its Effects on Chronic Lymphocytic Leukemia (CLL) Cell Migration,. Blood. 118(21). 3878–3878. 3 indexed citations

18.

Zboralski, Dirk, Bettina Warscheid, Susanne Klein‐Scory, et al.. (2010). Uncoupled responses of Smad4-deficient cancer cells to TNFα result in secretion of monomeric laminin-γ2. Molecular Cancer. 9(1). 65–65. 12 indexed citations

19.

Zboralski, Dirk, et al.. (2008). Divergent mechanisms underlie Smad4-mediated positive regulation of the three genes encoding the basement membrane component laminin-332 (laminin-5). BMC Cancer. 8(1). 215–215. 16 indexed citations

20.

Zapatka, Marc, Dirk Zboralski, Christiane Arnold, et al.. (2006). Basement membrane component laminin-5 is a target of the tumor suppressor Smad4. Oncogene. 26(10). 1417–1427. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact